Dyslipidemia and diabetic retinopathy

Review of Diabetic Studies

Volumn 10, Issue 2-3, 2013, Pages 121-132

  Chang, Yo Chen ^a,b   Wu, Wen Chuan ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Dyslipidemia; Type 2 diabetes

Indexed keywords

AMINOGUANIDINE; ANDROSTERONE; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN E; ATORVASTATIN; CD36 ANTIGEN; CHOLESTEROL; CLOFIBRATE; ETOFIBRATE; FENOFIBRATE; GALECTIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SCAVENGER RECEPTOR; SIMVASTATIN; TRIACYLGLYCEROL; VASCULOTROPIN;

ATHEROSCLEROSIS; BLOOD PRESSURE; DIABETES CONTROL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE SEVERITY; DYSLIPIDEMIA; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPID METABOLISM; MICROANEURYSM; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; REVIEW; RISK FACTOR; UNIVARIATE ANALYSIS; VISUAL ACUITY; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEINS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DYSLIPIDEMIAS; HUMANS; RISK FACTORS;

EID: 84891796627     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2013.10.121     Document Type: Review

References (82)

1. Cheung N, Mitchell P, Wong YT. Diabetic retinopathy. Lancet 2010. 376(9735):124-136.
2. Klein R, Klein BE. Are individuals with diabetes seeing better?-a long-term epidemiological perspective. Diabetes 2010. 59(8):1853-1860.
3. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998. 105(10):1801-1815.
4. Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, Sharrett AR, Shea S. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006. 141(3):446-455.
5. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy. A systemic review. JAMA 2007. 298(8):902-916.
6. Toussaint D, Cogan D, Kuwabara T. Extravascular lesions of diabetic retinopathy. Arch Ophthalmol 1962. 67(1):42-47.
7. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000. 284(3):311-318.
8. Rodgers A, MacMahon S, Yee T, Clark T. For the Eastern Stroke and Coronary Heart Disease Collaboration Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998. 352(9143):1801-1807.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993. 329(14):977-986.
10. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM, UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004. 122(11):1631-1640.
11. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991. 98(8):1261-1265.
12. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ, Miller D. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996. 114(9):1079-1084.
13. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, Turner RC, United Kingdom Prospective Diabetes Study 30. Diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998. 116(3):297-303.
14. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, Brancati FL, Hubbard LD, Couper D, ARIC Group. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the Atherosclerosis Risk in Communities study. Ophthalmology 2002. 109(7):1225-1234.
15. Klein R, Marino EK, Kuller LH, Polak JF, Tracy RP, Gottdiener JS, Burke GL, Hubbard LD, Boineau R. The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study. Br J Ophthalmol 2002. 86(1):84-90.
16. van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Polak BC. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care 2002. 25(8):1320-1325.
17. Hadjadj S, Duly-Bouhanick B, Bekherraz A, BrIdoux F, Gallois Y, Mauco G, Ebran J, Marre M. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 2004. 30(1):43-51.
18. Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 2004. 53(11):2883-2892.
19. Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, Sharrett AR, Shea S. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006. 141(3):446-455.
20. Rema M, Srivastava BK, Anitha B, Deepa R, Mohan V. Association of serum lipids with diabetic retinopathy in urban South Indians - the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-2. Diabet Med 2006. 23(9):1029-1036.
21. Ucgun NI, Yildirim Z, Kiliç N, Gürsel E. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann N Y Acad Sci 2007. 1100:213-217.
22. Golubovic-Arsovska M. Association of dyslipidaemia with macular oedema and hard exudates in diabetic maculopathy. Prilozi 2007. 28(2):149-160.
23. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, Lim SC, Tai ES, Mitchell P. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 2008. 115(11):1869-1875.
24. Popescu T, Mota M. Dyslipidemia and hypertension in patients with type 2 diabetes and retinopathy. Rom J Intern Med 2009. 47(3):235-241.
25. Sachdev N, Sahni A. Association of systemic risk factors with the severity of retinal hard exudates in a north Indian population with type 2 diabetes. J Postgrad Med 2010. 56(1):3-6.
26. Raman R, Rani PK, Kulothungan V, Rachepalle SR, Kumaramanickavel G, Sharma T. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. Ophthalmology 2010. 117(4):766-772.
27. Benarous R, Sasongko MB, Qureshi S, Fenwick E, Dirani M, Wong TY, Lamoureux EL. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci 2011. 52(10):7464-7469.
28. Wang S, Xu L, Jonas JB, You QS, Wang YX, Yang H. Dyslipidemia and eye diseases in the adult Chinese population: the Beijing eye study. Plos One 2012. 7(3):e26871.
29. Morton J, Zoungas S, Li Q, Patel AA, Chalmers J, Woodward M, Celermajer DS, Beulens JW, Stolk RP, Glasziou P, et al. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care 2012. 35(11):2201-2206.
30. Lim LS, Wong TY. Lipids and diabetic retinopathy. Expert Opin Biol Ther 2012. 12(1):93-105
31. Koya D and King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998. 47(6):859-866.
32. Wang QJ. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci 2006. 27(6):317-323.
33. Huang Q, Yuan Y. Interaction of PKC and NOS in signal transduction of microvascular hyperpermeability. Am J Physiol 1997. 273:H2442-H2451.
34. Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci 2010. 51(10):4867-4874.
35. Peppa M, Uribarri J, Vlassara H. Advanced glycation end products, and diabetes complications: what is new and what works. Clinical Diabetes 2003. 21(4):186-187.
36. Fathallah L, Obrosova IG. Increased retinal lipid peroxidation in early diabetes is not associated with ascorbate depletion or changes in ascorbate redox state. Exp Eye Res 2001. 72:719-723.
37. Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, Crabb JW, Salomon RG. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 2003. 278(43):42027-42035.
38. Zong H, Ward M, Stitt AW. AGEs, RAGE, and diabetic retinopathy. Current Diabetes Reports 2011. 11(4):244-252.
39. Hammes H P, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1992. 88(24):11555-11558.
40. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002. 48(3-4):171-180.
41. Smolders B, Lemmers R, Thijs V. Lipoprotein(a) and stroke: a meta-analysis of observational studies. Stroke 2007. 38(6):1959-1966.
42. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000. 102(10):1082-1085
43. Maioli M, Tonolo G, Pacifico A, Ciccarese M, Brizzi P, Kohner EM, Porta M. Raised serum apolipoprotein (a) in active diabetic retinopathy. Diabetologia 1993. 36(1):88-90.
44. Suehiro M, Ohkubo K, Kato H, Kido Y, Anzai K, Oshima K, Ono J. Analyses of serum lipoprotein(a) and the relation to phenotypes and genotypes of apolipoprotein(a) in type 2 diabetic patients with retinopathy. Exp Clin Endocrinol Diabetes 2002. 110(7):319-324.
45. Winocour PH, Bhatnagar D, Ishola M, Arrol S, Durrington PN. Lipoprotein (a) and microvascular disease in type 1 (insulin-dependent) diabetes. Diabet Med 1991. 8(10):922-927.
46. Boemi M, Sirolla C, Amadio L, Fumelli P, James RW. Lipoprotein(a) and retinopathy in IDDM and NIDDM patients. Diabetes Care 1997. 20(1):115.
47. Haffner SM, Klein BE, Moss SE, Klein R. Lp(a) is not related to retinopathy in diabetic subjects. Eur J Ophthalmol 1995. 5(2):119-123.
48. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993. 365(6448):762-764
49. Sinav S, Onelge MA, Onelge S, Sinav B. Plasma lipids and lipoproteins in retinopathy of type I (insulin-dependent) diabetic patients. Ann Ophthalmol 1993. 25(2):64-66.
50. Kawai S, Nakajima T, Hokari S, Komoda T, Kawai K. Apolipoprotein A-I concentration in tears in diabetic retinopathy. Ann Clin Biochem 2002. 39(1):56-61.
51. Santos A, Salguero ML, Gurrola C, Munoz F, Roig-Melo E, Panduro A. The epsilon4 allele of apolipoprotein E gene is a potential risk factor for the severity of macular edema in type 2 diabetic Mexican patients. Ophthalmic Genet 2002. 23(1):13-19.
52. Liew G, Shankar A, Wang JJ, Klein R, Bray MS, Couper DJ, Wong TY. Apolipoprotein E gene polymorphisms are not associated with diabetic retinopathy: the atherosclerosis risk in communities study. Am J Ophthalmol 2006. 142(1):105-111.
53. Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, et al. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications 2005. 19(1):18-25.
54. Simo R, Higuera M, Garcia-Ramirez M, Canals F, Garcia-Arumi J, Hernandez C. Elevation of apolipoprotein A-I and apolipoprotein H levels in the vitreous fluid and overexpression in the retina of diabetic patients. Arch Ophthalmol 2008. 126(8):1076-1081.
55. Sasongko MB, Wong TY, Nguyen TT, Kawasaki R, Jenkins A, Shaw J, Wang JJ. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care 2011. 34(2):474-479.
56. Hu A, Luo Y, Li T, Guo X, Ding X, Zhu X, Wang X, Tang S. Low serum apolipoprotein A1/B ratio is associated with proliferative diabetic retinopathy in type 2 diabetes. Graefes Arch Clin Exp Ophthalmol 2012. 250(7):957-962.
57. Dixon JL, Stoops JD, Parker JL, Laughlin MH, Weisman GA, Sturek M. Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. Arterioscler Thromb Vasc Biol 1999. 19(12):2981-2992.
58. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation 2001.104(2):2498-2502.
59. Hill SA, McQueen MJ. Reverse cholesterol transport - a review of the process and its clinical implications. Clin Biochem 1997. 30(7):517-525.
60. Tserentsoodol N, Gordiyenko NV, Pascual I, Lee JW, Fliesler SJ, Rodriguez IR. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol Vis 2006. 12:1319-1333.
61. Robbesyn F, Auge N, Vindis C, Cantero AV, Barbaras R, Negre-Salvayre A, Salvayre R. High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler Thromb Vasc Biol 2005. 25(8):1206-1212.
62. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 2006. 259(5):437-446.
63. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008. 372(9634):224-233.
64. Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol 2009. 32(9):482-486.
65. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984. 251(3):351-364.
66. National Heart, Lung, and Blood Institute Consensus Development Conference: Lowering blood cholesterol to prevent heart disease. JAMA 1985. 253(14):2080-2086.
67. Duncan LJ, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 1968. 17(7):458-467.
68. Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969, 18(5):285-291.
69. Cullen JF, Town SM, Campbell CJ. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 1994. 94(2):554-562.
70. Freyberger H, Schifferdecker E, Schatz H. Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent. Med Klin 1994. 89(11):594-597.
71. Emmerich KH, Poritis N, Stelmane I, Klindzane M, Erbler H, Goldsteine J, Goertelmeyer R. Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy. Klin. Monatblatter Augenheilkunde 2009. 226(7):561-567.
72. Havel E, Rencova J, Novak L, Blaha V, Solichova D, Bratova M, Zadak Z. Serum lipoproteins lowering and diabetic exudative retinopathy. Atherosclerosis 1997. 134(1-2):309.
73. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007. 370(9600):1687-1697.
74. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004. 110(2):227-239.
75. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyörälä K, Miettinen T, Wilhelmsen L, Olsson AG, et al. Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994. 344(8934):1383-1389.
76. Gordon B, Chang S, Kavanagh M, Berrocal M, Yannuzzi L, Robertson C, Drexler A. The effect of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991. 112(4):385-391.
77. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002. 56(1):1-11.
78. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004. 137(4):675-682.
79. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004. 364(9435):685-696.
80. Zhang J, McGwin G. Association of statin use with the risk of developing diabetic retinopathy. Arch Ophthalmol 2007. 125(8):1096-1099.
81. ACCORD Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010. 363(3):233-244.
82. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999. 353(9153):617-622.